Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.41 USD
Change Today -0.0091 / -2.19%
Volume 80.5K
PVCT On Other Exchanges
As of 1:54 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Biopharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Provectus Biopharmaceuticals, Inc. announced that they will report Q2, 2015 results at 1:00 PM, GMT Standard Time on Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals Mulls Acquisitions

Provectus Biopharmaceuticals, Inc. (AMEX:PVCT) filed a shelf registration in the amount of $100 million and intends to use the proceeds for the expansion of our business through internal growth or acquisitions.

Provectus Biopharmaceuticals, Inc. Signs Letter of Intent with Boehringer Ingelheim (China) Investment

Provectus Biopharmaceuticals, Inc. announced that it has signed a Letter of Intent (LOI) with Boehringer Ingelheim (China) Investment Co. Ltd. The purpose of the LOI is to lay a foundation for the two parties to collaborate in bringing PV-10, Provectus’ novel investigational drug for cancer, to market in mainland China, Hong Kong and Taiwan. Under the terms of the LOI, Boehringer will provide certain commercially reasonable support in the aspects of product registration with the China Food and Drug Administration (CFDA), communication preparation, market intelligence and other assistance to Provectus in China to the extent that is within Boehringer’s approved business scope and permissible by Chinese laws. In return, Provectus will grant Boehringer the first priority to be the exclusive collaborator of Provectus in China for PV-10 in the event that PV-10 is successfully registered and approved by the CFDA. The exclusive collaboration may take the form of exclusive distribution and promotion, exclusive licensing or other agreement, subject to both parties’ mutual agreement. At the appropriate time, Provectus and Boehringer will enter into a definitive agreement, including a non-compete provision, for PV-10 to be exclusively developed, distributed and promoted through the collaboration within China, although there can be no assurance that the parties will enter into a definitive agreement. In the LOI signed at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015 in Barcelona, the two parties have agreed to meet regularly and maintain effective communication in order to move forward with the registration and commercialization of the product and assess the potential cooperation between them in China, which may be adopted in a form of exclusive commercial supply, distribution and promotion, partnership or any other forms suitable to both parties’ interests.

Provectus Biopharmaceuticals, Inc. Announces Results of its Phase 1 Study of PV-10

Provectus Biopharmaceuticals, Inc. announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17thWorld Congress on Gastrointestinal Cancer (ESMO-GI). The main conclusion was that preliminary evidence of efficacy in treatment of liver cancers with PV-10 was observed. The poster presentation was made by Eric Wachter, Ph.D., Chief Technology Officer of Provectus. Provectus has previously reported data on clinical and nonclinical testing of intralesional PV-10, a 10% solution of rose bengal, as an investigational treatment for metastatic melanoma, where it has demonstrated high rates of complete response and durable local control in melanoma lesions. The current phase 1 study reported at ESMO-GI was designed to assess safety, pharmacokinetics, and preliminary efficacy of PV-10 in subjects with non-resectable HCC or other types of cancer metastatic to the liver. In the phase 1 liver study, subjects having a target lesion in the liver at least 1 cm in diameter were administered a single percutaneous injection of PV-10 into their target lesion. Plasma concentrations of PV-10 from 1 hour to 28 days after injection were measured. Radiologic assessments of the injected target lesion were performed to determine response over an initial 28-day and longer term 9-15 month follow-up period. Serum levels of potential liver injury markers were measured, and adverse events recorded. In the initial study cohort, six subjects received PV-10 injections in two successive escalating dose cohorts of 0.25 and 0.50 mL per cm3 lesion volume. Significant adverse events were limited to injection site and photosensitivity reactions that resolved without sequelae. All injected tumors were stable in size at 28 days, and among four of the initial six tumors that had longer-term assessment, two had partial response. Based on these data, the researchers concluded that preliminary efficacy in treatment of liver tumors with PV-10 was observed with acceptable tolerability.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $0.41 USD -0.0091

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at